Offerings (SEC Form D)
Each filing as reported by the issuer, newest first. Open a row for the full plain-English detail. D = original notice, D/A = amendment.
Offerings at a glance — 13 offerings, 20 filings (one row per SEC file number)
| File no. | Original Form D | Latest filing | Amendments | Offered (latest) | Sold (latest) | Industry (latest) |
|---|
| 021-399003 | May 11, 2021 EDGAR ↗ | May 11, 2021 D EDGAR ↗ | 0 | $27,000,054 | $27,000,054 | Biotechnology |
| 021-368000 | Jun 1, 2020 EDGAR ↗ | Jun 16, 2020 D/A EDGAR ↗ | 1 latest Jun 16, 2020 | $11,000,000 | $11,000,000 | Biotechnology |
| 021-353741 | Nov 19, 2019 EDGAR ↗ | Nov 19, 2019 D EDGAR ↗ | 0 | $16,800,000 | $9,300,000 | Biotechnology |
| 021-332002 | Feb 1, 2019 EDGAR ↗ | May 29, 2019 D/A EDGAR ↗ | 1 latest May 29, 2019 | $6,500,000 | $6,500,000 | Biotechnology |
| 021-287648 | May 30, 2017 EDGAR ↗ | May 30, 2017 D EDGAR ↗ | 0 | $5,000,000 | $5,000,000 | Biotechnology |
| 021-266987 | Jul 14, 2016 EDGAR ↗ | Jul 14, 2016 D EDGAR ↗ | 0 | $12,000,000 | $5,057,508 | Biotechnology |
| 021-252237 | Dec 2, 2015 EDGAR ↗ | Dec 2, 2015 D EDGAR ↗ | 0 | $8,500,000 | $3,634,048 | Biotechnology |
| 021-226362 | Oct 14, 2014 EDGAR ↗ | Apr 13, 2015 D/A EDGAR ↗ | 1 latest Apr 13, 2015 | $1,062,500 | $892,500 | Pharmaceuticals |
| 021-212797 | Mar 3, 2014 EDGAR ↗ | Mar 19, 2014 D/A EDGAR ↗ | 1 latest Mar 19, 2014 | $800,000 | $735,000 | Pharmaceuticals |
| 021-192110 | Feb 20, 2013 EDGAR ↗ | Feb 20, 2013 D EDGAR ↗ | 0 | $1,000,000 | $445,000 | Pharmaceuticals |
| 021-172560 | Jan 27, 2012 EDGAR ↗ | Jan 27, 2012 D EDGAR ↗ | 0 | $1,500,000 | $145,000 | Pharmaceuticals |
| 021-141408 | May 3, 2010 EDGAR ↗ | Jun 8, 2011 D/A EDGAR ↗ | 3 latest Jun 8, 2011 | $946,631 | $846,631 | Pharmaceuticals |
| 021-134383 | Sep 14, 2009 EDGAR ↗ | Sep 14, 2009 D EDGAR ↗ | 0 | $435,356 | $435,356 | Pharmaceuticals |
Offerings are grouped by SEC file number; rows without a file number (not yet retrieved from EDGAR) are shown as their own offering until the link is fetched.
May 11, 2021 D Biotechnology — $27,000,054 sold of $27,000,054 · 47 investors EDGAR ↗
| Filing | Form D filed May 11, 2021SEC file no. 021-399003 · accession 0001104659-21-064649 |
|---|
| Raise progress | $27,000,054 sold of $27,000,054 offered (100%) · $0 remaining · first sale Apr 28, 2021 |
|---|
| Filing timing | Date of first sale: Apr 28, 2021 · Form D filed: May 11, 2021 (13 days after first sale) Rule: a Form D is generally due within 15 days after the first sale. Both dates are shown as reported; no conclusion is drawn. |
|---|
| Time since first sale | 2,005 days (5.5 years) |
|---|
| Annual amendments | Issuer reported the offering is not expected to last more than one year. No amendment for this offering in our index (filings 2008 → Oct 22, 2026; checked Oct 23, 2026, 5:45 PM ET). Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn. |
|---|
| Investors | 47 total · issuer reported no non-accredited investors |
|---|
| Exemption claimed | Rule 506(b) — no general advertising; up to 35 non-accredited investors allowed |
|---|
| Minimum investment accepted | $0 as filed (no minimum reported) |
|---|
| Securities offered | Equity; Option, warrant or other right to acquire; Security to be acquired upon exercise |
|---|
| Entity details | Organized in DELAWARE · formed more than five years before filing · revenue range: Decline to Disclose (state and year as reported on the issuer's latest filing) As reported by the issuer on Form D (Items 1–2 and 5). |
|---|
| Industry | Biotechnology |
|---|
| Who is paid to sell it | Ladenburg Thalmann & Co. Inc. — FINRA BrokerCheck CRD 505 ↗ Solicits in: All States |
|---|
| Money to insiders | Sales commissions: $410,000 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $1,300,000 (est.) |
|---|
| Signed by | Purnanand D. Sarma, Ph.D., President and Chief Executive Officer (May 11, 2021) |
|---|
| Market context | Minimum investment: $0 as filed (no minimum reported). Typical range for similar offerings: $10,000–$50,000.
Offering size: $27,000,054. Typical range: $2,000,000–$19,999,994.
Investors: 47. Typical range: 2–16."Similar" = Biotechnology, Rule 506(b). Based on 3,253 Form D filings 2021–2026 in the same industry and exemption (Biotechnology, Rule 506(b); original Form D notices, one per offering) (Form D data, SEC). Ranges are the middle half (25th–75th percentile) of the filings that reported each value: minimum investment 704, offering size 3,078, investors 3,148. Computed by PartnerFacts as of Oct 23, 2026, 5:45 PM ET. No ranking or score. Source: PartnerFacts data & coverage. |
|---|
| Source | This filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set · PartnerFacts data last updated Oct 23, 2026, 5:45 PM ET |
|---|
Jun 16, 2020 D/A Biotechnology — $11,000,000 sold of $11,000,000 · 49 investors EDGAR ↗
| Filing | Form D/A (amendment) filed Jun 16, 2020 · amends 0001472012-20-000001 ↗SEC file no. 021-368000 · accession 0001472012-20-000002 · filing 2 of 2 in this offering |
|---|
| Raise progress | $11,000,000 sold of $11,000,000 offered (100%) · $0 remaining · first sale Jun 2, 2020 |
|---|
| Filing timing | Date of first sale: Jun 2, 2020 · Original Form D filed: Jun 1, 2020 (1 day before first sale) · This amendment (Form D/A) filed: Jun 16, 2020 This row is an amendment. Rule: the original Form D is generally due within 15 days after the first sale; the rule sets no deadline measured from an amendment. Dates shown as reported; no conclusion is drawn. |
|---|
| Time since first sale | 2,335 days (6.4 years) |
|---|
| Annual amendments | Issuer reported the offering is not expected to last more than one year. This filing is an amendment dated Jun 16, 2020. Most recent amendment for this offering in our index: this filing, Jun 16, 2020. Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn. |
|---|
| Investors | 49 total · issuer reported no non-accredited investors |
|---|
| Exemption claimed | Rule 506(b) — no general advertising; up to 35 non-accredited investors allowed |
|---|
| Minimum investment accepted | $0 as filed (no minimum reported) |
|---|
| Securities offered | Equity; Option, warrant or other right to acquire; Security to be acquired upon exercise; Other: Shares of Common Stock Issuable Upon Conversion of Series A Preferred Stock |
|---|
| Entity details | Organized in DELAWARE · formed more than five years before filing · revenue range: Decline to Disclose (state and year as reported on the issuer's latest filing) As reported by the issuer on Form D (Items 1–2 and 5). |
|---|
| Industry | Biotechnology |
|---|
| Who is paid to sell it | No sales compensation recipients listed on this filing. |
|---|
| Money to insiders | Sales commissions: $0 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $330,000 (est.) |
|---|
| Signed by | Purnanand Sarma, CEO (Jun 16, 2020) |
|---|
| Changes vs previous filing | - total sold: $0 (Jun 1, 2020) → $11,000,000 (Jun 16, 2020)
- remaining: $11,000,000 (Jun 1, 2020) → $0 (Jun 16, 2020)
- investors: 0 (Jun 1, 2020) → 49 (Jun 16, 2020)
- date of first sale: Yet to occur (Jun 1, 2020) → Jun 2, 2020 (Jun 16, 2020)
- securities offered: Equity; Other: Shares of Common Stock Issuable Upon Conversion of Series A Preferred Stock (Jun 1, 2020) → Equity; Option, warrant or other right to acquire; Security to be acquired upon exercise; Other: Shares of Common Stock Issuable Upon Conversion of Series A Preferred Stock (Jun 16, 2020)
Compared with the D filed Jun 1, 2020 ( EDGAR ↗). Fields compared: total sold, total offering, remaining, investors, non-accredited investors (count), non-accredited investors reported, minimum investment, sales commissions, finder's fees, proceeds to insiders, date of first sale, industry, fund type, exemption, revenue range, net asset value range, securities offered, may last more than one year, related persons, sales-compensation recipients. Amendment history as filed; no conclusion is drawn. |
|---|
| Market context | Minimum investment: $0 as filed (no minimum reported). Typical range for similar offerings: $10,000–$50,000.
Offering size: $11,000,000. Typical range: $2,000,000–$19,999,994.
Investors: 49. Typical range: 2–16."Similar" = Biotechnology, Rule 506(b). Based on 3,253 Form D filings 2021–2026 in the same industry and exemption (Biotechnology, Rule 506(b); original Form D notices, one per offering) (Form D data, SEC). Ranges are the middle half (25th–75th percentile) of the filings that reported each value: minimum investment 704, offering size 3,078, investors 3,148. Computed by PartnerFacts as of Oct 23, 2026, 5:45 PM ET. No ranking or score. Source: PartnerFacts data & coverage. |
|---|
| Source | This filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set · PartnerFacts data last updated Oct 23, 2026, 5:45 PM ET |
|---|
Jun 1, 2020 D Biotechnology — $0 sold of $11,000,000 · 0 investors EDGAR ↗
| Filing | Form D filed Jun 1, 2020SEC file no. 021-368000 · accession 0001472012-20-000001 · filing 1 of 2 in this offering |
|---|
| Raise progress | $0 sold of $11,000,000 offered (0%) · $11,000,000 remaining |
|---|
| Filing timing | Date of first sale: Yet to occur · Form D filed: Jun 1, 2020 Rule: a Form D is generally due within 15 days after the first sale. Both dates are shown as reported; no conclusion is drawn. |
|---|
| Annual amendments | Issuer reported the offering is not expected to last more than one year. Most recent amendment for this offering in our index: Jun 16, 2020 (EDGAR ↗). Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn. |
|---|
| Investors | 0 total · issuer reported no non-accredited investors |
|---|
| Exemption claimed | Rule 506(b) — no general advertising; up to 35 non-accredited investors allowed |
|---|
| Minimum investment accepted | $0 as filed (no minimum reported) |
|---|
| Securities offered | Equity; Other: Shares of Common Stock Issuable Upon Conversion of Series A Preferred Stock |
|---|
| Entity details | Organized in DELAWARE · formed more than five years before filing · revenue range: Decline to Disclose (state and year as reported on the issuer's latest filing) As reported by the issuer on Form D (Items 1–2 and 5). |
|---|
| Industry | Biotechnology |
|---|
| Who is paid to sell it | No sales compensation recipients listed on this filing. |
|---|
| Money to insiders | Sales commissions: $0 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $330,000 |
|---|
| Signed by | Purnanand Sarma, CEO (May 29, 2020) |
|---|
| Market context | Minimum investment: $0 as filed (no minimum reported). Typical range for similar offerings: $10,000–$50,000.
Offering size: $11,000,000. Typical range: $2,000,000–$19,999,994.
Investors: 0. Typical range: 2–16."Similar" = Biotechnology, Rule 506(b). Based on 3,253 Form D filings 2021–2026 in the same industry and exemption (Biotechnology, Rule 506(b); original Form D notices, one per offering) (Form D data, SEC). Ranges are the middle half (25th–75th percentile) of the filings that reported each value: minimum investment 704, offering size 3,078, investors 3,148. Computed by PartnerFacts as of Oct 23, 2026, 5:45 PM ET. No ranking or score. Source: PartnerFacts data & coverage. |
|---|
| Source | This filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set · PartnerFacts data last updated Oct 23, 2026, 5:45 PM ET |
|---|
Nov 19, 2019 D Biotechnology — $9,300,000 sold of $16,800,000 · 35 investors EDGAR ↗
| Filing | Form D filed Nov 19, 2019SEC file no. 021-353741 · accession 0001472012-19-000004 |
|---|
| Raise progress | $9,300,000 sold of $16,800,000 offered (55%) · $7,500,000 remaining · first sale Nov 4, 2019 Issuer's note: Inclusive of proceeds from conversion of Notes. Series A financing expansion - to occur in multiple closings |
|---|
| Filing timing | Date of first sale: Nov 4, 2019 · Form D filed: Nov 19, 2019 (15 days after first sale) Rule: a Form D is generally due within 15 days after the first sale. Both dates are shown as reported; no conclusion is drawn. |
|---|
| Time since first sale | 2,546 days (7.0 years) |
|---|
| Annual amendments | Issuer reported the offering is not expected to last more than one year. No amendment for this offering in our index (filings 2008 → Oct 22, 2026; checked Oct 23, 2026, 5:45 PM ET). Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn. |
|---|
| Investors | 35 total · issuer reported no non-accredited investors |
|---|
| Exemption claimed | Rule 506(b) — no general advertising; up to 35 non-accredited investors allowed |
|---|
| Minimum investment accepted | $0 as filed (no minimum reported) |
|---|
| Securities offered | Equity; Other: Shares of common stock issuable upon conversion of Series A preferred stock |
|---|
| Entity details | Organized in DELAWARE · formed more than five years before filing · revenue range: Decline to Disclose (state and year as reported on the issuer's latest filing) As reported by the issuer on Form D (Items 1–2 and 5). |
|---|
| Industry | Biotechnology |
|---|
| Who is paid to sell it | No sales compensation recipients listed on this filing. |
|---|
| Money to insiders | Sales commissions: $0 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $500,000 (est.) |
|---|
| Signed by | Purnanand Sarma, CEO (Nov 19, 2019) |
|---|
| Market context | Minimum investment: $0 as filed (no minimum reported). Typical range for similar offerings: $10,000–$50,000.
Offering size: $16,800,000. Typical range: $2,000,000–$19,999,994.
Investors: 35. Typical range: 2–16."Similar" = Biotechnology, Rule 506(b). Based on 3,253 Form D filings 2021–2026 in the same industry and exemption (Biotechnology, Rule 506(b); original Form D notices, one per offering) (Form D data, SEC). Ranges are the middle half (25th–75th percentile) of the filings that reported each value: minimum investment 704, offering size 3,078, investors 3,148. Computed by PartnerFacts as of Oct 23, 2026, 5:45 PM ET. No ranking or score. Source: PartnerFacts data & coverage. |
|---|
| Source | This filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set · PartnerFacts data last updated Oct 23, 2026, 5:45 PM ET |
|---|
May 29, 2019 D/A Biotechnology — $6,500,000 sold of $6,500,000 · 27 investors EDGAR ↗
| Filing | Form D/A (amendment) filed May 29, 2019 · amends 0001472012-19-000002 ↗SEC file no. 021-332002 · accession 0001472012-19-000003 · filing 2 of 2 in this offering |
|---|
| Raise progress | $6,500,000 sold of $6,500,000 offered (100%) · $0 remaining · first sale Feb 7, 2019 |
|---|
| Filing timing | Date of first sale: Feb 7, 2019 · Original Form D filed: Feb 1, 2019 (6 days before first sale) · This amendment (Form D/A) filed: May 29, 2019 This row is an amendment. Rule: the original Form D is generally due within 15 days after the first sale; the rule sets no deadline measured from an amendment. Dates shown as reported; no conclusion is drawn. |
|---|
| Time since first sale | 2,816 days (7.7 years) |
|---|
| Annual amendments | Issuer reported the offering is not expected to last more than one year. This filing is an amendment dated May 29, 2019. Most recent amendment for this offering in our index: this filing, May 29, 2019. Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn. |
|---|
| Investors | 27 total · issuer reported no non-accredited investors |
|---|
| Exemption claimed | Rule 506(b) — no general advertising; up to 35 non-accredited investors allowed |
|---|
| Minimum investment accepted | $0 as filed (no minimum reported) |
|---|
| Securities offered | Debt; Option, warrant or other right to acquire; Security to be acquired upon exercise |
|---|
| Entity details | Organized in DELAWARE · formed more than five years before filing · revenue range: Decline to Disclose (state and year as reported on the issuer's latest filing) As reported by the issuer on Form D (Items 1–2 and 5). |
|---|
| Industry | Biotechnology |
|---|
| Who is paid to sell it | No sales compensation recipients listed on this filing. |
|---|
| Money to insiders | Sales commissions: $0 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $315,000 |
|---|
| Signed by | Philip R. Wagenheim, Secretary (May 28, 2019) |
|---|
| Changes vs previous filing | - total sold: $0 (Feb 1, 2019) → $6,500,000 (May 29, 2019)
- total offering: $5,000,000 (Feb 1, 2019) → $6,500,000 (May 29, 2019)
- remaining: $5,000,000 (Feb 1, 2019) → $0 (May 29, 2019)
- investors: 0 (Feb 1, 2019) → 27 (May 29, 2019)
- date of first sale: Yet to occur (Feb 1, 2019) → Feb 7, 2019 (May 29, 2019)
Compared with the D filed Feb 1, 2019 ( EDGAR ↗). Fields compared: total sold, total offering, remaining, investors, non-accredited investors (count), non-accredited investors reported, minimum investment, sales commissions, finder's fees, proceeds to insiders, date of first sale, industry, fund type, exemption, revenue range, net asset value range, securities offered, may last more than one year, related persons, sales-compensation recipients. Amendment history as filed; no conclusion is drawn. |
|---|
| Market context | Minimum investment: $0 as filed (no minimum reported). Typical range for similar offerings: $10,000–$50,000.
Offering size: $6,500,000. Typical range: $2,000,000–$19,999,994.
Investors: 27. Typical range: 2–16."Similar" = Biotechnology, Rule 506(b). Based on 3,253 Form D filings 2021–2026 in the same industry and exemption (Biotechnology, Rule 506(b); original Form D notices, one per offering) (Form D data, SEC). Ranges are the middle half (25th–75th percentile) of the filings that reported each value: minimum investment 704, offering size 3,078, investors 3,148. Computed by PartnerFacts as of Oct 23, 2026, 5:45 PM ET. No ranking or score. Source: PartnerFacts data & coverage. |
|---|
| Source | This filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set · PartnerFacts data last updated Oct 23, 2026, 5:45 PM ET |
|---|
Feb 1, 2019 D Biotechnology — $0 sold of $5,000,000 · 0 investors EDGAR ↗
| Filing | Form D filed Feb 1, 2019SEC file no. 021-332002 · accession 0001472012-19-000002 · filing 1 of 2 in this offering |
|---|
| Raise progress | $0 sold of $5,000,000 offered (0%) · $5,000,000 remaining |
|---|
| Filing timing | Date of first sale: Yet to occur · Form D filed: Feb 1, 2019 Rule: a Form D is generally due within 15 days after the first sale. Both dates are shown as reported; no conclusion is drawn. |
|---|
| Annual amendments | Issuer reported the offering is not expected to last more than one year. Most recent amendment for this offering in our index: May 29, 2019 (EDGAR ↗). Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn. |
|---|
| Investors | 0 total · issuer reported no non-accredited investors |
|---|
| Exemption claimed | Rule 506(b) — no general advertising; up to 35 non-accredited investors allowed |
|---|
| Minimum investment accepted | $0 as filed (no minimum reported) |
|---|
| Securities offered | Debt; Option, warrant or other right to acquire; Security to be acquired upon exercise |
|---|
| Entity details | Organized in DELAWARE · formed more than five years before filing · revenue range: Decline to Disclose (state and year as reported on the issuer's latest filing) As reported by the issuer on Form D (Items 1–2 and 5). |
|---|
| Industry | Biotechnology |
|---|
| Who is paid to sell it | No sales compensation recipients listed on this filing. |
|---|
| Money to insiders | Sales commissions: $0 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $315,000 |
|---|
| Signed by | Michael J. Morin, CEO (Feb 1, 2019) |
|---|
| Market context | Minimum investment: $0 as filed (no minimum reported). Typical range for similar offerings: $10,000–$50,000.
Offering size: $5,000,000. Typical range: $2,000,000–$19,999,994.
Investors: 0. Typical range: 2–16."Similar" = Biotechnology, Rule 506(b). Based on 3,253 Form D filings 2021–2026 in the same industry and exemption (Biotechnology, Rule 506(b); original Form D notices, one per offering) (Form D data, SEC). Ranges are the middle half (25th–75th percentile) of the filings that reported each value: minimum investment 704, offering size 3,078, investors 3,148. Computed by PartnerFacts as of Oct 23, 2026, 5:45 PM ET. No ranking or score. Source: PartnerFacts data & coverage. |
|---|
| Source | This filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set · PartnerFacts data last updated Oct 23, 2026, 5:45 PM ET |
|---|
May 30, 2017 D Biotechnology — $5,000,000 sold of $5,000,000 · 48 investors EDGAR ↗
| Filing | Form D filed May 30, 2017SEC file no. 021-287648 · accession 0001472012-17-000003 |
|---|
| Raise progress | $5,000,000 sold of $5,000,000 offered (100%) · $0 remaining · first sale May 17, 2017 |
|---|
| Filing timing | Date of first sale: May 17, 2017 · Form D filed: May 30, 2017 (13 days after first sale) Rule: a Form D is generally due within 15 days after the first sale. Both dates are shown as reported; no conclusion is drawn. |
|---|
| Time since first sale | 3,447 days (9.4 years) |
|---|
| Annual amendments | Issuer reported the offering is not expected to last more than one year. No amendment for this offering in our index (filings 2008 → Oct 22, 2026; checked Oct 23, 2026, 5:45 PM ET). Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn. |
|---|
| Investors | 48 total · issuer reported no non-accredited investors |
|---|
| Exemption claimed | Rule 506(b) — no general advertising; up to 35 non-accredited investors allowed |
|---|
| Minimum investment accepted | $0 as filed (no minimum reported) |
|---|
| Securities offered | Equity; Option, warrant or other right to acquire; Security to be acquired upon exercise |
|---|
| Entity details | Organized in DELAWARE · formed more than five years before filing · revenue range: Decline to Disclose (state and year as reported on the issuer's latest filing) As reported by the issuer on Form D (Items 1–2 and 5). |
|---|
| Industry | Biotechnology |
|---|
| Who is paid to sell it | No sales compensation recipients listed on this filing. |
|---|
| Money to insiders | Sales commissions: $0 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $315,000 |
|---|
| Signed by | David Kutcher, CFO and Treasurer (May 30, 2017) |
|---|
| Market context | Minimum investment: $0 as filed (no minimum reported). Typical range for similar offerings: $10,000–$50,000.
Offering size: $5,000,000. Typical range: $2,000,000–$19,999,994.
Investors: 48. Typical range: 2–16."Similar" = Biotechnology, Rule 506(b). Based on 3,253 Form D filings 2021–2026 in the same industry and exemption (Biotechnology, Rule 506(b); original Form D notices, one per offering) (Form D data, SEC). Ranges are the middle half (25th–75th percentile) of the filings that reported each value: minimum investment 704, offering size 3,078, investors 3,148. Computed by PartnerFacts as of Oct 23, 2026, 5:45 PM ET. No ranking or score. Source: PartnerFacts data & coverage. |
|---|
| Source | This filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set · PartnerFacts data last updated Oct 23, 2026, 5:45 PM ET |
|---|
Jul 14, 2016 D Biotechnology — $5,057,508 sold of $12,000,000 · 27 investors EDGAR ↗
| Filing | Form D filed Jul 14, 2016SEC file no. 021-266987 · accession 0001472012-16-000006 |
|---|
| Raise progress | $5,057,508 sold of $12,000,000 offered (42%) · $6,942,492 remaining · first sale Jul 1, 2016 |
|---|
| Filing timing | Date of first sale: Jul 1, 2016 · Form D filed: Jul 14, 2016 (13 days after first sale) Rule: a Form D is generally due within 15 days after the first sale. Both dates are shown as reported; no conclusion is drawn. |
|---|
| Time since first sale | 3,767 days (10.3 years) |
|---|
| Annual amendments | Issuer reported the offering is not expected to last more than one year. No amendment for this offering in our index (filings 2008 → Oct 22, 2026; checked Oct 23, 2026, 5:45 PM ET). Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn. |
|---|
| Investors | 27 total · issuer reported no non-accredited investors |
|---|
| Exemption claimed | Rule 506(b) — no general advertising; up to 35 non-accredited investors allowed |
|---|
| Minimum investment accepted | $0 as filed (no minimum reported) |
|---|
| Securities offered | Equity; Security to be acquired upon exercise |
|---|
| Entity details | Organized in DELAWARE · formed more than five years before filing · revenue range: Decline to Disclose (state and year as reported on the issuer's latest filing) As reported by the issuer on Form D (Items 1–2 and 5). |
|---|
| Industry | Biotechnology |
|---|
| Who is paid to sell it | No sales compensation recipients listed on this filing. |
|---|
| Money to insiders | Sales commissions: $0 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $756,000 (est.) |
|---|
| Signed by | Jane H. Hollingsworth, Chief Executive Officer (Jul 14, 2016) |
|---|
| Market context | Minimum investment: $0 as filed (no minimum reported). Typical range for similar offerings: $10,000–$50,000.
Offering size: $12,000,000. Typical range: $2,000,000–$19,999,994.
Investors: 27. Typical range: 2–16."Similar" = Biotechnology, Rule 506(b). Based on 3,253 Form D filings 2021–2026 in the same industry and exemption (Biotechnology, Rule 506(b); original Form D notices, one per offering) (Form D data, SEC). Ranges are the middle half (25th–75th percentile) of the filings that reported each value: minimum investment 704, offering size 3,078, investors 3,148. Computed by PartnerFacts as of Oct 23, 2026, 5:45 PM ET. No ranking or score. Source: PartnerFacts data & coverage. |
|---|
| Source | This filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set · PartnerFacts data last updated Oct 23, 2026, 5:45 PM ET |
|---|
Dec 2, 2015 D Biotechnology — $3,634,048 sold of $8,500,000 · 18 investors EDGAR ↗
| Filing | Form D filed Dec 2, 2015SEC file no. 021-252237 · accession 0001472012-15-000002 |
|---|
| Raise progress | $3,634,048 sold of $8,500,000 offered (43%) · $4,865,952 remaining · first sale Nov 18, 2015 |
|---|
| Filing timing | Date of first sale: Nov 18, 2015 · Form D filed: Dec 2, 2015 (14 days after first sale) Rule: a Form D is generally due within 15 days after the first sale. Both dates are shown as reported; no conclusion is drawn. |
|---|
| Time since first sale | 3,993 days (10.9 years) |
|---|
| Annual amendments | Issuer reported the offering may last more than one year. No amendment for this offering in our index (filings 2008 → Oct 22, 2026; checked Oct 23, 2026, 5:45 PM ET). Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn. |
|---|
| Investors | 18 total · issuer reported no non-accredited investors |
|---|
| Exemption claimed | Rule 506(b) — no general advertising; up to 35 non-accredited investors allowed |
|---|
| Minimum investment accepted | $0 as filed (no minimum reported) |
|---|
| Securities offered | Equity; Option, warrant or other right to acquire; Security to be acquired upon exercise |
|---|
| Entity details | Organized in DELAWARE · formed more than five years before filing · revenue range: Decline to Disclose (state and year as reported on the issuer's latest filing) As reported by the issuer on Form D (Items 1–2 and 5). |
|---|
| Industry | Biotechnology |
|---|
| Who is paid to sell it | None — no CRD number reported · associated broker-dealer: Broadband Capital Management LLC (CRD 48001 ↗) Solicits in: CT, FL, NC, NY, PA, WI |
|---|
| Money to insiders | Sales commissions: $0 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $472,000 |
|---|
| Signed by | Jane H. Hollingsworth, Executive Chair and President (Dec 2, 2015) |
|---|
| Market context | Minimum investment: $0 as filed (no minimum reported). Typical range for similar offerings: $10,000–$50,000.
Offering size: $8,500,000. Typical range: $2,000,000–$19,999,994.
Investors: 18. Typical range: 2–16."Similar" = Biotechnology, Rule 506(b). Based on 3,253 Form D filings 2021–2026 in the same industry and exemption (Biotechnology, Rule 506(b); original Form D notices, one per offering) (Form D data, SEC). Ranges are the middle half (25th–75th percentile) of the filings that reported each value: minimum investment 704, offering size 3,078, investors 3,148. Computed by PartnerFacts as of Oct 23, 2026, 5:45 PM ET. No ranking or score. Source: PartnerFacts data & coverage. |
|---|
| Source | This filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set · PartnerFacts data last updated Oct 23, 2026, 5:45 PM ET |
|---|
Apr 13, 2015 D/A Pharmaceuticals — $892,500 sold of $1,062,500 · 17 investors EDGAR ↗
| Filing | Form D/A (amendment) filed Apr 13, 2015 · amends 0001472012-14-000003 ↗SEC file no. 021-226362 · accession 0001472012-15-000001 · filing 2 of 2 in this offering |
|---|
| Raise progress | $892,500 sold of $1,062,500 offered (84%) · $170,000 remaining · first sale Sep 30, 2014 |
|---|
| Filing timing | Date of first sale: Sep 30, 2014 · Original Form D filed: Oct 14, 2014 (14 days after first sale) · This amendment (Form D/A) filed: Apr 13, 2015 This row is an amendment. Rule: the original Form D is generally due within 15 days after the first sale; the rule sets no deadline measured from an amendment. Dates shown as reported; no conclusion is drawn. |
|---|
| Time since first sale | 4,407 days (12.1 years) |
|---|
| Annual amendments | Issuer reported the offering is not expected to last more than one year. This filing is an amendment dated Apr 13, 2015. Most recent amendment for this offering in our index: this filing, Apr 13, 2015. Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn. |
|---|
| Investors | 17 total · issuer reported no non-accredited investors |
|---|
| Exemption claimed | Rule 506(b) — no general advertising; up to 35 non-accredited investors allowed |
|---|
| Minimum investment accepted | $5,000 |
|---|
| Securities offered | Debt; Option, warrant or other right to acquire; Security to be acquired upon exercise |
|---|
| Entity details | Organized in DELAWARE · formed more than five years before filing · revenue range: Decline to Disclose (state and year as reported on the issuer's latest filing) As reported by the issuer on Form D (Items 1–2 and 5). |
|---|
| Industry | Pharmaceuticals |
|---|
| Who is paid to sell it | No sales compensation recipients listed on this filing. |
|---|
| Money to insiders | Sales commissions: $0 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $162,500 (est.) |
|---|
| Signed by | Jane H. Hollingsworth, Executive Chair (Apr 13, 2015) |
|---|
| Changes vs previous filing | - total sold: $467,500 (Oct 14, 2014) → $892,500 (Apr 13, 2015)
- total offering: $650,000 (Oct 14, 2014) → $1,062,500 (Apr 13, 2015)
- remaining: $182,500 (Oct 14, 2014) → $170,000 (Apr 13, 2015)
- investors: 14 (Oct 14, 2014) → 17 (Apr 13, 2015)
- proceeds to insiders: $100,000 (Oct 14, 2014) → $162,500 (Apr 13, 2015)
Compared with the D filed Oct 14, 2014 ( EDGAR ↗). Fields compared: total sold, total offering, remaining, investors, non-accredited investors (count), non-accredited investors reported, minimum investment, sales commissions, finder's fees, proceeds to insiders, date of first sale, industry, fund type, exemption, revenue range, net asset value range, securities offered, may last more than one year, related persons, sales-compensation recipients. Amendment history as filed; no conclusion is drawn. |
|---|
| Market context | Minimum investment: $5,000. Typical range for similar offerings: $10,000–$55,000.
Offering size: $1,062,500. Typical range: $1,694,259–$16,000,000.
Investors: 17. Typical range: 1–13."Similar" = Pharmaceuticals, Rule 506(b). Based on 800 Form D filings 2021–2026 in the same industry and exemption (Pharmaceuticals, Rule 506(b); original Form D notices, one per offering) (Form D data, SEC). Ranges are the middle half (25th–75th percentile) of the filings that reported each value: minimum investment 186, offering size 758, investors 770. Computed by PartnerFacts as of Oct 23, 2026, 5:45 PM ET. No ranking or score. Source: PartnerFacts data & coverage. |
|---|
| Source | This filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set · PartnerFacts data last updated Oct 23, 2026, 5:45 PM ET |
|---|
Oct 14, 2014 D Pharmaceuticals — $467,500 sold of $650,000 · 14 investors EDGAR ↗
| Filing | Form D filed Oct 14, 2014SEC file no. 021-226362 · accession 0001472012-14-000003 · filing 1 of 2 in this offering |
|---|
| Raise progress | $467,500 sold of $650,000 offered (72%) · $182,500 remaining · first sale Sep 30, 2014 |
|---|
| Filing timing | Date of first sale: Sep 30, 2014 · Form D filed: Oct 14, 2014 (14 days after first sale) Rule: a Form D is generally due within 15 days after the first sale. Both dates are shown as reported; no conclusion is drawn. |
|---|
| Time since first sale | 4,407 days (12.1 years) |
|---|
| Annual amendments | Issuer reported the offering is not expected to last more than one year. Most recent amendment for this offering in our index: Apr 13, 2015 (EDGAR ↗). Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn. |
|---|
| Investors | 14 total · issuer reported no non-accredited investors |
|---|
| Exemption claimed | Rule 506(b) — no general advertising; up to 35 non-accredited investors allowed |
|---|
| Minimum investment accepted | $5,000 |
|---|
| Securities offered | Debt; Option, warrant or other right to acquire; Security to be acquired upon exercise |
|---|
| Entity details | Organized in DELAWARE · formed more than five years before filing · revenue range: Decline to Disclose (state and year as reported on the issuer's latest filing) As reported by the issuer on Form D (Items 1–2 and 5). |
|---|
| Industry | Pharmaceuticals |
|---|
| Who is paid to sell it | No sales compensation recipients listed on this filing. |
|---|
| Money to insiders | Sales commissions: $0 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $100,000 |
|---|
| Signed by | Joel Sussman, Chief Financial Officer (Oct 14, 2014) |
|---|
| Market context | Minimum investment: $5,000. Typical range for similar offerings: $10,000–$55,000.
Offering size: $650,000. Typical range: $1,694,259–$16,000,000.
Investors: 14. Typical range: 1–13."Similar" = Pharmaceuticals, Rule 506(b). Based on 800 Form D filings 2021–2026 in the same industry and exemption (Pharmaceuticals, Rule 506(b); original Form D notices, one per offering) (Form D data, SEC). Ranges are the middle half (25th–75th percentile) of the filings that reported each value: minimum investment 186, offering size 758, investors 770. Computed by PartnerFacts as of Oct 23, 2026, 5:45 PM ET. No ranking or score. Source: PartnerFacts data & coverage. |
|---|
| Source | This filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set · PartnerFacts data last updated Oct 23, 2026, 5:45 PM ET |
|---|
Mar 19, 2014 D/A Pharmaceuticals — $735,000 sold of $800,000 · 23 investors EDGAR ↗
| Filing | Form D/A (amendment) filed Mar 19, 2014 · amends 0001472012-14-000001 ↗SEC file no. 021-212797 · accession 0001472012-14-000002 · filing 2 of 2 in this offering |
|---|
| Raise progress | $735,000 sold of $800,000 offered (92%) · $65,000 remaining · first sale Feb 19, 2014 |
|---|
| Filing timing | Date of first sale: Feb 19, 2014 · Original Form D filed: Mar 3, 2014 (12 days after first sale) · This amendment (Form D/A) filed: Mar 19, 2014 This row is an amendment. Rule: the original Form D is generally due within 15 days after the first sale; the rule sets no deadline measured from an amendment. Dates shown as reported; no conclusion is drawn. |
|---|
| Time since first sale | 4,630 days (12.7 years) |
|---|
| Annual amendments | Issuer reported the offering is not expected to last more than one year. This filing is an amendment dated Mar 19, 2014. Most recent amendment for this offering in our index: this filing, Mar 19, 2014. Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn. |
|---|
| Investors | 23 total · issuer reported no non-accredited investors |
|---|
| Exemption claimed | Rule 506(b) — no general advertising; up to 35 non-accredited investors allowed |
|---|
| Minimum investment accepted | $0 as filed (no minimum reported) |
|---|
| Securities offered | Debt; Option, warrant or other right to acquire; Security to be acquired upon exercise |
|---|
| Entity details | Organized in DELAWARE · formed more than five years before filing · revenue range: Decline to Disclose (state and year as reported on the issuer's latest filing) As reported by the issuer on Form D (Items 1–2 and 5). |
|---|
| Industry | Pharmaceuticals |
|---|
| Who is paid to sell it | No sales compensation recipients listed on this filing. |
|---|
| Money to insiders | Sales commissions: $0 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $80,000 |
|---|
| Signed by | Joel H. Sussman, Chief Financial Officer (Mar 19, 2014) |
|---|
| Changes vs previous filing | - total sold: $200,000 (Mar 3, 2014) → $735,000 (Mar 19, 2014)
- total offering: $600,000 (Mar 3, 2014) → $800,000 (Mar 19, 2014)
- remaining: $400,000 (Mar 3, 2014) → $65,000 (Mar 19, 2014)
- investors: 1 (Mar 3, 2014) → 23 (Mar 19, 2014)
- proceeds to insiders: $60,000 (Mar 3, 2014) → $80,000 (Mar 19, 2014)
- related persons added (Mar 19, 2014): Joel H. Sussman
Compared with the D filed Mar 3, 2014 ( EDGAR ↗). Fields compared: total sold, total offering, remaining, investors, non-accredited investors (count), non-accredited investors reported, minimum investment, sales commissions, finder's fees, proceeds to insiders, date of first sale, industry, fund type, exemption, revenue range, net asset value range, securities offered, may last more than one year, related persons, sales-compensation recipients. Amendment history as filed; no conclusion is drawn. |
|---|
| Market context | Minimum investment: $0 as filed (no minimum reported). Typical range for similar offerings: $10,000–$55,000.
Offering size: $800,000. Typical range: $1,694,259–$16,000,000.
Investors: 23. Typical range: 1–13."Similar" = Pharmaceuticals, Rule 506(b). Based on 800 Form D filings 2021–2026 in the same industry and exemption (Pharmaceuticals, Rule 506(b); original Form D notices, one per offering) (Form D data, SEC). Ranges are the middle half (25th–75th percentile) of the filings that reported each value: minimum investment 186, offering size 758, investors 770. Computed by PartnerFacts as of Oct 23, 2026, 5:45 PM ET. No ranking or score. Source: PartnerFacts data & coverage. |
|---|
| Source | This filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set · PartnerFacts data last updated Oct 23, 2026, 5:45 PM ET |
|---|
Mar 3, 2014 D Pharmaceuticals — $200,000 sold of $600,000 · 1 investors EDGAR ↗
| Filing | Form D filed Mar 3, 2014SEC file no. 021-212797 · accession 0001472012-14-000001 · filing 1 of 2 in this offering |
|---|
| Raise progress | $200,000 sold of $600,000 offered (33%) · $400,000 remaining · first sale Feb 19, 2014 |
|---|
| Filing timing | Date of first sale: Feb 19, 2014 · Form D filed: Mar 3, 2014 (12 days after first sale) Rule: a Form D is generally due within 15 days after the first sale. Both dates are shown as reported; no conclusion is drawn. |
|---|
| Time since first sale | 4,630 days (12.7 years) |
|---|
| Annual amendments | Issuer reported the offering is not expected to last more than one year. Most recent amendment for this offering in our index: Mar 19, 2014 (EDGAR ↗). Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn. |
|---|
| Investors | 1 total · issuer reported no non-accredited investors |
|---|
| Exemption claimed | Rule 506(b) — no general advertising; up to 35 non-accredited investors allowed |
|---|
| Minimum investment accepted | $0 as filed (no minimum reported) |
|---|
| Securities offered | Debt; Option, warrant or other right to acquire; Security to be acquired upon exercise |
|---|
| Entity details | Organized in DELAWARE · formed more than five years before filing · revenue range: Decline to Disclose (state and year as reported on the issuer's latest filing) As reported by the issuer on Form D (Items 1–2 and 5). |
|---|
| Industry | Pharmaceuticals |
|---|
| Who is paid to sell it | No sales compensation recipients listed on this filing. |
|---|
| Money to insiders | Sales commissions: $0 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $60,000 |
|---|
| Signed by | Jane H. Hollingsworth, Chief Executive Officer (Mar 3, 2014) |
|---|
| Market context | Minimum investment: $0 as filed (no minimum reported). Typical range for similar offerings: $10,000–$55,000.
Offering size: $600,000. Typical range: $1,694,259–$16,000,000.
Investors: 1. Typical range: 1–13."Similar" = Pharmaceuticals, Rule 506(b). Based on 800 Form D filings 2021–2026 in the same industry and exemption (Pharmaceuticals, Rule 506(b); original Form D notices, one per offering) (Form D data, SEC). Ranges are the middle half (25th–75th percentile) of the filings that reported each value: minimum investment 186, offering size 758, investors 770. Computed by PartnerFacts as of Oct 23, 2026, 5:45 PM ET. No ranking or score. Source: PartnerFacts data & coverage. |
|---|
| Source | This filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set · PartnerFacts data last updated Oct 23, 2026, 5:45 PM ET |
|---|
Feb 20, 2013 D Pharmaceuticals — $445,000 sold of $1,000,000 · 9 investors EDGAR ↗
| Filing | Form D filed Feb 20, 2013SEC file no. 021-192110 · accession 0001472012-13-000001 |
|---|
| Raise progress | $445,000 sold of $1,000,000 offered (45%) · $555,000 remaining · first sale Feb 8, 2013 Issuer's note: Includes proceeds from the cancellation of indebtedness of the Issuer |
|---|
| Filing timing | Date of first sale: Feb 8, 2013 · Form D filed: Feb 20, 2013 (12 days after first sale) Rule: a Form D is generally due within 15 days after the first sale. Both dates are shown as reported; no conclusion is drawn. |
|---|
| Time since first sale | 5,006 days (13.7 years) |
|---|
| Annual amendments | Issuer reported the offering is not expected to last more than one year. No amendment for this offering in our index (filings 2008 → Oct 22, 2026; checked Oct 23, 2026, 5:45 PM ET). Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn. |
|---|
| Investors | 9 total · issuer reported no non-accredited investors |
|---|
| Exemption claimed | Rule 506 (filed before Sept 2013, when 506 was split into 506(b) and 506(c)) |
|---|
| Minimum investment accepted | $10,000 |
|---|
| Securities offered | Debt; Option, warrant or other right to acquire; Security to be acquired upon exercise |
|---|
| Entity details | Organized in DELAWARE · formed more than five years before filing · revenue range: Decline to Disclose (state and year as reported on the issuer's latest filing) As reported by the issuer on Form D (Items 1–2 and 5). |
|---|
| Industry | Pharmaceuticals |
|---|
| Who is paid to sell it | No sales compensation recipients listed on this filing. |
|---|
| Money to insiders | Sales commissions: $0 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $30,000 |
|---|
| Signed by | Timothy J. Pelura, President and Chief Executive Officer (Feb 20, 2013) |
|---|
| Market context | Not computed — the exemption as filed is Rule 506 before the Sept 2013 split into 506(b) and 506(c) (see Exemption claimed); ranges are computed only for offerings claiming Rule 506(b) or 506(c), compared with the last 5 years of filings. |
|---|
| Source | This filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set · PartnerFacts data last updated Oct 23, 2026, 5:45 PM ET |
|---|
Jan 27, 2012 D Pharmaceuticals — $145,000 sold of $1,500,000 · 4 investors EDGAR ↗
| Filing | Form D filed Jan 27, 2012SEC file no. 021-172560 · accession 0001472012-12-000003 |
|---|
| Raise progress | $145,000 sold of $1,500,000 offered (10%) · $1,355,000 remaining · first sale Jan 4, 2012 |
|---|
| Filing timing | Date of first sale: Jan 4, 2012 · Form D filed: Jan 27, 2012 (23 days after first sale) Rule: a Form D is generally due within 15 days after the first sale. Both dates are shown as reported; no conclusion is drawn. |
|---|
| Time since first sale | 5,407 days (14.8 years) |
|---|
| Annual amendments | Issuer reported the offering is not expected to last more than one year. No amendment for this offering in our index (filings 2008 → Oct 22, 2026; checked Oct 23, 2026, 5:45 PM ET). Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn. |
|---|
| Investors | 4 total · issuer reported no non-accredited investors |
|---|
| Exemption claimed | Rule 506 (filed before Sept 2013, when 506 was split into 506(b) and 506(c)) |
|---|
| Minimum investment accepted | $25,000 |
|---|
| Securities offered | Debt; Option, warrant or other right to acquire; Security to be acquired upon exercise |
|---|
| Entity details | Organized in DELAWARE · formed more than five years before filing · revenue range: Decline to Disclose (state and year as reported on the issuer's latest filing) As reported by the issuer on Form D (Items 1–2 and 5). |
|---|
| Industry | Pharmaceuticals |
|---|
| Who is paid to sell it | No sales compensation recipients listed on this filing. |
|---|
| Money to insiders | Sales commissions: $0 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $90,000 (est.) |
|---|
| Signed by | Timothy J. Pelura, President and Chief Executive Officer (Jan 27, 2012) |
|---|
| Market context | Not computed — the exemption as filed is Rule 506 before the Sept 2013 split into 506(b) and 506(c) (see Exemption claimed); ranges are computed only for offerings claiming Rule 506(b) or 506(c), compared with the last 5 years of filings. |
|---|
| Source | This filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set · PartnerFacts data last updated Oct 23, 2026, 5:45 PM ET |
|---|
Jun 8, 2011 D/A Pharmaceuticals — $846,631 sold of $946,631 · 5 investors EDGAR ↗
| Filing | Form D/A (amendment) filed Jun 8, 2011 · amends 0001472012-10-000003 ↗SEC file no. 021-141408 · accession 0001472012-11-000001 · filing 4 of 4 in this offering |
|---|
| Raise progress | $846,631 sold of $946,631 offered (89%) · $100,000 remaining · first sale Apr 19, 2010 |
|---|
| Filing timing | Date of first sale: Apr 19, 2010 · Original Form D filed: May 3, 2010 (14 days after first sale) · This amendment (Form D/A) filed: Jun 8, 2011 This row is an amendment. Rule: the original Form D is generally due within 15 days after the first sale; the rule sets no deadline measured from an amendment. Dates shown as reported; no conclusion is drawn. |
|---|
| Time since first sale | 6,032 days (16.5 years) |
|---|
| Annual amendments | Issuer reported the offering may last more than one year. This filing is an amendment dated Jun 8, 2011. Most recent amendment for this offering in our index: this filing, Jun 8, 2011. Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn. |
|---|
| Investors | 5 total · issuer reported no non-accredited investors |
|---|
| Exemption claimed | Rule 506 (filed before Sept 2013, when 506 was split into 506(b) and 506(c)) |
|---|
| Minimum investment accepted | $25,000 |
|---|
| Securities offered | Debt; Option, warrant or other right to acquire; Security to be acquired upon exercise |
|---|
| Entity details | Organized in DELAWARE · formed more than five years before filing · revenue range: No Revenues (state and year as reported on the issuer's latest filing) As reported by the issuer on Form D (Items 1–2 and 5). |
|---|
| Industry | Pharmaceuticals |
|---|
| Who is paid to sell it | No sales compensation recipients listed on this filing. |
|---|
| Money to insiders | Sales commissions: $0 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $100,000 (est.) |
|---|
| Signed by | Timothy J. Pelura, President and Chief Executive Officer (Jun 8, 2011) |
|---|
| Changes vs previous filing | - total sold: $446,631 (Oct 5, 2010) → $846,631 (Jun 8, 2011)
- remaining: $500,000 (Oct 5, 2010) → $100,000 (Jun 8, 2011)
- investors: 2 (Oct 5, 2010) → 5 (Jun 8, 2011)
- may last more than one year: no (Oct 5, 2010) → yes (Jun 8, 2011)
Compared with the D/A filed Oct 5, 2010 ( EDGAR ↗). Fields compared: total sold, total offering, remaining, investors, non-accredited investors (count), non-accredited investors reported, minimum investment, sales commissions, finder's fees, proceeds to insiders, date of first sale, industry, fund type, exemption, revenue range, net asset value range, securities offered, may last more than one year, related persons, sales-compensation recipients. Amendment history as filed; no conclusion is drawn. |
|---|
| Market context | Not computed — the exemption as filed is Rule 506 before the Sept 2013 split into 506(b) and 506(c) (see Exemption claimed); ranges are computed only for offerings claiming Rule 506(b) or 506(c), compared with the last 5 years of filings. |
|---|
| Source | This filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set · PartnerFacts data last updated Oct 23, 2026, 5:45 PM ET |
|---|
Oct 5, 2010 D/A Pharmaceuticals — $446,631 sold of $946,631 · 2 investors EDGAR ↗
| Filing | Form D/A (amendment) filed Oct 5, 2010 · amends 0001472012-10-000002 ↗SEC file no. 021-141408 · accession 0001472012-10-000003 · filing 3 of 4 in this offering |
|---|
| Raise progress | $446,631 sold of $946,631 offered (47%) · $500,000 remaining · first sale Apr 19, 2010 |
|---|
| Filing timing | Date of first sale: Apr 19, 2010 · Original Form D filed: May 3, 2010 (14 days after first sale) · This amendment (Form D/A) filed: Oct 5, 2010 This row is an amendment. Rule: the original Form D is generally due within 15 days after the first sale; the rule sets no deadline measured from an amendment. Dates shown as reported; no conclusion is drawn. |
|---|
| Time since first sale | 6,032 days (16.5 years) |
|---|
| Annual amendments | Issuer reported the offering is not expected to last more than one year. This filing is an amendment dated Oct 5, 2010. Most recent amendment for this offering in our index: Jun 8, 2011 (EDGAR ↗). Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn. |
|---|
| Investors | 2 total · issuer reported no non-accredited investors |
|---|
| Exemption claimed | Rule 506 (filed before Sept 2013, when 506 was split into 506(b) and 506(c)) |
|---|
| Minimum investment accepted | $25,000 |
|---|
| Securities offered | Debt; Option, warrant or other right to acquire; Security to be acquired upon exercise |
|---|
| Entity details | Organized in DELAWARE · formed more than five years before filing · revenue range: No Revenues (state and year as reported on the issuer's latest filing) As reported by the issuer on Form D (Items 1–2 and 5). |
|---|
| Industry | Pharmaceuticals |
|---|
| Who is paid to sell it | No sales compensation recipients listed on this filing. |
|---|
| Money to insiders | Sales commissions: $0 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $100,000 (est.) |
|---|
| Signed by | Timothy J. Pelura, President and Chief Executive Officer (Oct 1, 2010) |
|---|
| Changes vs previous filing | - related persons added (Oct 5, 2010): Barbara S. Schilberg
- related persons no longer listed (Oct 5, 2010): Gregory P. Licholai
Compared with the D/A filed Oct 4, 2010 ( EDGAR ↗). Fields compared: total sold, total offering, remaining, investors, non-accredited investors (count), non-accredited investors reported, minimum investment, sales commissions, finder's fees, proceeds to insiders, date of first sale, industry, fund type, exemption, revenue range, net asset value range, securities offered, may last more than one year, related persons, sales-compensation recipients. Amendment history as filed; no conclusion is drawn. |
|---|
| Market context | Not computed — the exemption as filed is Rule 506 before the Sept 2013 split into 506(b) and 506(c) (see Exemption claimed); ranges are computed only for offerings claiming Rule 506(b) or 506(c), compared with the last 5 years of filings. |
|---|
| Source | This filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set · PartnerFacts data last updated Oct 23, 2026, 5:45 PM ET |
|---|
Oct 4, 2010 D/A Pharmaceuticals — $446,631 sold of $946,631 · 2 investors EDGAR ↗
| Filing | Form D/A (amendment) filed Oct 4, 2010 · amends 0001472012-10-000001 ↗SEC file no. 021-141408 · accession 0001472012-10-000002 · filing 2 of 4 in this offering |
|---|
| Raise progress | $446,631 sold of $946,631 offered (47%) · $500,000 remaining · first sale Apr 19, 2010 |
|---|
| Filing timing | Date of first sale: Apr 19, 2010 · Original Form D filed: May 3, 2010 (14 days after first sale) · This amendment (Form D/A) filed: Oct 4, 2010 This row is an amendment. Rule: the original Form D is generally due within 15 days after the first sale; the rule sets no deadline measured from an amendment. Dates shown as reported; no conclusion is drawn. |
|---|
| Time since first sale | 6,032 days (16.5 years) |
|---|
| Annual amendments | Issuer reported the offering is not expected to last more than one year. This filing is an amendment dated Oct 4, 2010. Most recent amendment for this offering in our index: Jun 8, 2011 (EDGAR ↗). Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn. |
|---|
| Investors | 2 total · issuer reported no non-accredited investors |
|---|
| Exemption claimed | Rule 506 (filed before Sept 2013, when 506 was split into 506(b) and 506(c)) |
|---|
| Minimum investment accepted | $25,000 |
|---|
| Securities offered | Debt; Option, warrant or other right to acquire; Security to be acquired upon exercise |
|---|
| Entity details | Organized in DELAWARE · formed more than five years before filing · revenue range: No Revenues (state and year as reported on the issuer's latest filing) As reported by the issuer on Form D (Items 1–2 and 5). |
|---|
| Industry | Pharmaceuticals |
|---|
| Who is paid to sell it | No sales compensation recipients listed on this filing. |
|---|
| Money to insiders | Sales commissions: $0 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $100,000 (est.) |
|---|
| Signed by | Timothy J. Pelura, President and Chief Executive Officer (Oct 1, 2010) |
|---|
| Changes vs previous filing | - total sold: $346,631 (May 3, 2010) → $446,631 (Oct 4, 2010)
- total offering: $846,631 (May 3, 2010) → $946,631 (Oct 4, 2010)
Compared with the D filed May 3, 2010 ( EDGAR ↗). Fields compared: total sold, total offering, remaining, investors, non-accredited investors (count), non-accredited investors reported, minimum investment, sales commissions, finder's fees, proceeds to insiders, date of first sale, industry, fund type, exemption, revenue range, net asset value range, securities offered, may last more than one year, related persons, sales-compensation recipients. Amendment history as filed; no conclusion is drawn. |
|---|
| Market context | Not computed — the exemption as filed is Rule 506 before the Sept 2013 split into 506(b) and 506(c) (see Exemption claimed); ranges are computed only for offerings claiming Rule 506(b) or 506(c), compared with the last 5 years of filings. |
|---|
| Source | This filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set · PartnerFacts data last updated Oct 23, 2026, 5:45 PM ET |
|---|
May 3, 2010 D Pharmaceuticals — $346,631 sold of $846,631 · 2 investors EDGAR ↗
| Filing | Form D filed May 3, 2010SEC file no. 021-141408 · accession 0001472012-10-000001 · filing 1 of 4 in this offering |
|---|
| Raise progress | $346,631 sold of $846,631 offered (41%) · $500,000 remaining · first sale Apr 19, 2010 |
|---|
| Filing timing | Date of first sale: Apr 19, 2010 · Form D filed: May 3, 2010 (14 days after first sale) Rule: a Form D is generally due within 15 days after the first sale. Both dates are shown as reported; no conclusion is drawn. |
|---|
| Time since first sale | 6,032 days (16.5 years) |
|---|
| Annual amendments | Issuer reported the offering is not expected to last more than one year. Most recent amendment for this offering in our index: Jun 8, 2011 (EDGAR ↗). Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn. |
|---|
| Investors | 2 total · issuer reported no non-accredited investors |
|---|
| Exemption claimed | Rule 506 (filed before Sept 2013, when 506 was split into 506(b) and 506(c)) |
|---|
| Minimum investment accepted | $25,000 |
|---|
| Securities offered | Debt; Option, warrant or other right to acquire; Security to be acquired upon exercise |
|---|
| Entity details | Organized in DELAWARE · formed more than five years before filing · revenue range: No Revenues (state and year as reported on the issuer's latest filing) As reported by the issuer on Form D (Items 1–2 and 5). |
|---|
| Industry | Pharmaceuticals |
|---|
| Who is paid to sell it | No sales compensation recipients listed on this filing. |
|---|
| Money to insiders | Sales commissions: $0 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $100,000 (est.) |
|---|
| Signed by | Timothy J. Pelura, President and Chief Executive Officer (Apr 30, 2010) |
|---|
| Market context | Not computed — the exemption as filed is Rule 506 before the Sept 2013 split into 506(b) and 506(c) (see Exemption claimed); ranges are computed only for offerings claiming Rule 506(b) or 506(c), compared with the last 5 years of filings. |
|---|
| Source | This filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set · PartnerFacts data last updated Oct 23, 2026, 5:45 PM ET |
|---|
Sep 14, 2009 D Pharmaceuticals — $435,356 sold of $435,356 · 6 investors EDGAR ↗
| Filing | Form D filed Sep 14, 2009SEC file no. 021-134383 · accession 0001472012-09-000001 |
|---|
| Raise progress | $435,356 sold of $435,356 offered (100%) · $0 remaining · first sale Sep 3, 2009 Issuer's note: Further proceeds include exercise price of Warrants to be issued at a later date. Such exercise price is not yet determinable under the terms of the Warrants. Therefore, the exercise price is not included in this Item 13. |
|---|
| Filing timing | Date of first sale: Sep 3, 2009 · Form D filed: Sep 14, 2009 (11 days after first sale) Rule: a Form D is generally due within 15 days after the first sale. Both dates are shown as reported; no conclusion is drawn. |
|---|
| Time since first sale | 6,260 days (17.2 years) |
|---|
| Annual amendments | Issuer reported the offering is not expected to last more than one year. No amendment for this offering in our index (filings 2008 → Oct 22, 2026; checked Oct 23, 2026, 5:45 PM ET). Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn. |
|---|
| Investors | 6 total · issuer reported no non-accredited investors |
|---|
| Exemption claimed | Rule 506 (filed before Sept 2013, when 506 was split into 506(b) and 506(c)) |
|---|
| Minimum investment accepted | $25,000 |
|---|
| Securities offered | Debt; Option, warrant or other right to acquire; Security to be acquired upon exercise |
|---|
| Entity details | Organized in DELAWARE · formed more than five years before filing · revenue range: No Revenues (state and year as reported on the issuer's latest filing) As reported by the issuer on Form D (Items 1–2 and 5). |
|---|
| Industry | Pharmaceuticals |
|---|
| Who is paid to sell it | No sales compensation recipients listed on this filing. |
|---|
| Money to insiders | Sales commissions: $0 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $100,000 (est.) |
|---|
| Signed by | Scott K. Dessain, M.D., Ph.D., President (Sep 11, 2009) |
|---|
| Market context | Not computed — the exemption as filed is Rule 506 before the Sept 2013 split into 506(b) and 506(c) (see Exemption claimed); ranges are computed only for offerings claiming Rule 506(b) or 506(c), compared with the last 5 years of filings. |
|---|
| Source | This filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set · PartnerFacts data last updated Oct 23, 2026, 5:45 PM ET |
|---|
Amendment history — 7 amendments on this page, each compared with the filing before it in the same offering
| Amendment filed | File no. | Compared with | What changed (both values as filed) |
|---|
| Jun 16, 2020 EDGAR ↗ | 021-368000 | Jun 1, 2020 D | total sold: $0 (Jun 1, 2020) → $11,000,000 (Jun 16, 2020) · remaining: $11,000,000 (Jun 1, 2020) → $0 (Jun 16, 2020) · investors: 0 (Jun 1, 2020) → 49 (Jun 16, 2020) · and 2 more (open the filing above) |
| May 29, 2019 EDGAR ↗ | 021-332002 | Feb 1, 2019 D | total sold: $0 (Feb 1, 2019) → $6,500,000 (May 29, 2019) · total offering: $5,000,000 (Feb 1, 2019) → $6,500,000 (May 29, 2019) · remaining: $5,000,000 (Feb 1, 2019) → $0 (May 29, 2019) · and 2 more (open the filing above) |
| Apr 13, 2015 EDGAR ↗ | 021-226362 | Oct 14, 2014 D | total sold: $467,500 (Oct 14, 2014) → $892,500 (Apr 13, 2015) · total offering: $650,000 (Oct 14, 2014) → $1,062,500 (Apr 13, 2015) · remaining: $182,500 (Oct 14, 2014) → $170,000 (Apr 13, 2015) · and 2 more (open the filing above) |
| Mar 19, 2014 EDGAR ↗ | 021-212797 | Mar 3, 2014 D | total sold: $200,000 (Mar 3, 2014) → $735,000 (Mar 19, 2014) · total offering: $600,000 (Mar 3, 2014) → $800,000 (Mar 19, 2014) · remaining: $400,000 (Mar 3, 2014) → $65,000 (Mar 19, 2014) · and 3 more (open the filing above) |
| Jun 8, 2011 EDGAR ↗ | 021-141408 | Oct 5, 2010 D/A | total sold: $446,631 (Oct 5, 2010) → $846,631 (Jun 8, 2011) · remaining: $500,000 (Oct 5, 2010) → $100,000 (Jun 8, 2011) · investors: 2 (Oct 5, 2010) → 5 (Jun 8, 2011) · and 1 more (open the filing above) |
| Oct 5, 2010 EDGAR ↗ | 021-141408 | Oct 4, 2010 D/A | related persons added (Oct 5, 2010): Barbara S. Schilberg · related persons no longer listed (Oct 5, 2010): Gregory P. Licholai |
| Oct 4, 2010 EDGAR ↗ | 021-141408 | May 3, 2010 D | total sold: $346,631 (May 3, 2010) → $446,631 (Oct 4, 2010) · total offering: $846,631 (May 3, 2010) → $946,631 (Oct 4, 2010) |
Fields compared: total sold, total offering, remaining, investors, non-accredited investors (count), non-accredited investors reported, minimum investment, sales commissions, finder's fees, proceeds to insiders, date of first sale, industry, fund type, exemption, revenue range, net asset value range, securities offered, may last more than one year, related persons, sales-compensation recipients. Values as filed; no conclusion is drawn.
All Form D filings for this CIK on SEC EDGAR ↗. History: 0 new offerings in the last 12 months (new offering = a Form D that is not an amendment) · most recent filing May 11, 2021. Industry as reported, by offering: Previous offerings: Pharmaceuticals (2009–2014). Latest offering: Biotechnology (2015–2021; most recent May 11, 2021).
Key people 23
Officers, directors and promoters the issuer itself named on its Form D. Tap a name for every other deal they are on.
| Name | Relationship | Address state | On filings (first → last) | Also listed on |
|---|
| CR Corleen Roche | Executive Officer | MA | May 11, 2021 on 1 of 20 filings listed on the latest filing | — |
| DG Dennis H Giesing | Executive Officer | MA | May 11, 2021 on 1 of 20 filings listed on the latest filing | — |
| JL John LaMattina | Director | PA | Feb 1, 2019 → May 11, 2021 on 6 of 20 filings listed on the latest filing | 2 other issuers |
| MW Michael D Widlitz also filed as Michael D. Widlitz | Director | PA | Sep 14, 2009 → May 11, 2021 on 18 of 20 filings listed on the latest filing | — |
| MM Michael J Morin also filed as Michael J. Morin | Executive Officer, Director | PA | Jul 14, 2016 → May 11, 2021 on 8 of 20 filings listed on the latest filing | — |
| ML Michael Lefenfeld | Director | PA | Feb 1, 2019 → May 11, 2021 on 6 of 20 filings listed on the latest filing | 2 other issuers |
| MR Michael Rapp | Director | MA | May 11, 2021 on 1 of 20 filings listed on the latest filing | 1 other issuer |
| PW Philip Wagenheim also filed as Philip R. Wagenheim; Philip R Wagenheim | Director, Executive Officer | PA | Dec 2, 2015 → May 11, 2021 on 9 of 20 filings listed on the latest filing | 4 other issuers |
| PS Purnanand Sarma | Executive Officer, Director | PA | Nov 19, 2019 → May 11, 2021 on 4 of 20 filings listed on the latest filing | 2 other issuers |
| RB Richard Baron | Director | MA | May 11, 2021 on 1 of 20 filings listed on the latest filing | — |
| SS Sandra G Stoneman | Executive Officer | MA | May 11, 2021 on 1 of 20 filings listed on the latest filing | — |
| IM I Wistar Morris also filed as I. Wistar Morris | Director | PA | Sep 14, 2009 → Jun 16, 2020 on 19 of 20 filings not listed on the latest filing (May 11, 2021) | 7 other issuers |
| MR Michael D Rapoport also filed as Michael D. Rapoport | Director | PA | Dec 2, 2015 → Jun 16, 2020 on 8 of 20 filings not listed on the latest filing (May 11, 2021) | 1 other issuer |
| DK David Kutcher | Executive Officer | PA | May 30, 2017 → Nov 19, 2019 on 4 of 20 filings not listed on the latest filing (May 11, 2021) | — |
| SD Scott Dessain also filed as Scott K. Dessain | Executive Officer, Director | PA | Sep 14, 2009 → Nov 19, 2019 on 15 of 20 filings not listed on the latest filing (May 11, 2021) | — |
| GH Gregory Harriman | Director | PA | Feb 20, 2013 → May 30, 2017 on 8 of 20 filings not listed on the latest filing (May 11, 2021) | — |
| JH Jane H. Hollingsworth | Executive Officer, Director | PA | Mar 3, 2014 → Jul 14, 2016 on 6 of 20 filings not listed on the latest filing (May 11, 2021) | 1 other issuer |
| JS Joel Sussman also filed as Joel H. Sussman | Executive Officer | PA | Mar 19, 2014 → Dec 2, 2015 on 4 of 20 filings not listed on the latest filing (May 11, 2021) | 3 other issuers |
| JL Joan Lau | Executive Officer | PA | Mar 3, 2014 → Apr 13, 2015 on 4 of 20 filings not listed on the latest filing (May 11, 2021) | 1 other issuer |
| GH George Hobbs | Director, Executive Officer | PA | May 3, 2010 → Feb 20, 2013 on 6 of 20 filings not listed on the latest filing (May 11, 2021) | — |
| TP Timothy J. Pelura | Executive Officer, Director | PA | May 3, 2010 → Feb 20, 2013 on 6 of 20 filings not listed on the latest filing (May 11, 2021) | — |
| BS Barbara S. Schilberg | Director | PA | Oct 5, 2010 → Jan 27, 2012 on 3 of 20 filings not listed on the latest filing (May 11, 2021) | 1 other issuer |
| GL Gregory P. Licholai | Director | PA | Sep 14, 2009 → Oct 4, 2010 on 3 of 20 filings not listed on the latest filing (May 11, 2021) | — |
Executive officers, directors and promoters as self-reported by the issuer, one row per person. Spellings of the same name (same first and last name, or the same full name that EDGAR split differently into middle and last name) with no conflicting middle initial are shown on one row (none on this issuer); dates and counts come from the filings that list each name. Licensed persons: FINRA BrokerCheck ↗ · SEC IAPD ↗. Middle names: the SEC Form D data set (RELATEDPERSONS.tsv) repeats the previous person's middle name into later rows of the same filing; where that happened PartnerFacts shows the name without the repeated middle name and keeps the data-set spelling on record (Corleen J Roche; John R. LaMattina; John R LaMattina; John J LaMattina; Michael R. Lefenfeld; Michael R Lefenfeld; Michael J Lefenfeld; Michael J Rapp; Philip J Wagenheim; Richard J Baron; David D. Kutcher; Scott D. Dessain; Gregory D. Harriman; Gregory K. Harriman; Gregory R. Harriman; Joel Wistar Sussman; Joan H. Lau; George P. Hobbs; George S. Hobbs; George D. Hobbs) — the filing on EDGAR is the source.
Connections
Other issuers listing the same people:
- Terrestrial Bio, Inc. — Purnanand Sarma · latest filing Mar 19, 2026
- Galera Therapeutics, Inc. — Joel Sussman · latest filing Jan 14, 2025
- VEDANTA BIOSCIENCES, INC. — John LaMattina · latest filing Aug 5, 2024
- ONE Group Hospitality, Inc. — Michael Rapp · latest filing May 14, 2024
- ONE Group Hospitality, Inc. — Philip R. Wagenheim · latest filing May 14, 2024
- Annovis Bio, Inc. — Barbara S. Schilberg · latest filing Apr 25, 2023
- Hydrobuilder Holdings LLC — Michael Lefenfeld · latest filing Jun 11, 2021
- Hydrobuilder Holdings LLC — Michael D. Rapoport · latest filing Jun 11, 2021
- Hydrobuilder Holdings LLC — Philip R. Wagenheim · latest filing Jun 11, 2021
- Hydro Stores Investment Corp I LLC — Philip R. Wagenheim · latest filing Jan 25, 2021
- Complexa Inc. — I. Wistar Morris · latest filing Apr 16, 2019
- PhaseBio Pharmaceuticals Inc — Joel Sussman · latest filing Sep 10, 2018
- PTC 450, Ltd. — I. Wistar Morris · latest filing Jul 20, 2018
- MELINTA THERAPEUTICS, INC. /NEW/ — I. Wistar Morris · latest filing Jan 19, 2018
- Gelesis Inc — John LaMattina · latest filing Dec 30, 2015
- SiGNa Chemistry, Inc. — Michael Lefenfeld · latest filing Feb 11, 2015
- RhoQ Inc. — I. Wistar Morris · latest filing Oct 8, 2014
- BHM Funding, LLC — Philip R. Wagenheim · latest filing May 21, 2013
- TARIS BIOMEDICAL INC — Purnanand Sarma · latest filing Apr 4, 2013
- NUPATHE INC. — Jane H. Hollingsworth · latest filing Nov 6, 2012
- Azelon Pharmaceuticals, Inc. — Joan Lau · latest filing Mar 16, 2012
- ODYSSEY VALUE FUND OFFSHORE LTD — I. Wistar Morris · latest filing May 27, 2011
- ODYSSEY VALUE FUND LP — I. Wistar Morris · latest filing May 26, 2011
- BOENNING & SCATTERGOOD HOLDINGS INC — I. Wistar Morris · latest filing May 28, 2010
- Ascenta Therapeutics, Inc. — Joel Sussman · latest filing Feb 5, 2010
Shared address: this business address appears on no other issuer's filings in our index. As of Oct 23, 2026, 5:45 PM ET.
Other offering types (Regulation A and Regulation Crowdfunding)
None found in sources searched.
Sources searched: SEC Regulation A Data Sets (Forms 1-A, 1-K, 1-Z; 2015 Q2 → 2026 Q3); SEC Crowdfunding Offerings Data Sets (Form C family; 2016 Q2 → 2026 Q3); EDGAR form index for 2026 Q3 → 2026 Q4 · Last checked Oct 23, 2026, 8:41 PM ET.
Adviser registration (Form ADV)
Not yet searched. Sources to be searched: SEC Investment Adviser Information Reports — Form ADV data for SEC-registered advisers and exempt reporting advisers (file dated 2026-10-02); SEC Investment Adviser Public Disclosure (IAPD) firm search — registered and exempt reporting advisers · Search queued. Results are added automatically; check back later.
Meta advertising
Meta advertising Meta Pixel and page links found on the sponsor's own site; ads from Meta's Ad Library where the API returns them
Not yet searched.
Sources to be searched: the sponsor's website (none on record yet; a sponsor's website is known only from the issuer's own filings (Form C issuer website; EDGAR company profile), an approved profile claim or Form ADV Item 1.I of its matched adviser — we never look it up elsewhere) for Meta Pixel ids and Facebook / Instagram page links; Meta Ad Library API: not yet searched (API access pending). We never read facebook.com or instagram.com; readers get a link to Meta's public Ad Library instead.
Public profiles
Public profiles official links and public statements, each with its source and date
Not found in sources searched.
Sources searched for a website: Form C data set (issuer websites as filed), Form ADV data set (Item 1.I of matched advisers) — as of Oct 23, 2026, 11:20 PM ET: none on file for this issuer. The sponsor website, the Internet Archive and GDELT news index are read only once a site is on file; a sponsor's website is known only from the issuer's own filings (Form C issuer website; EDGAR company profile), an approved profile claim or Form ADV Item 1.I of its matched adviser — we never look it up elsewhere. We never collect personal or family accounts.
Entity standing: not checked (no official programmatic source for MA yet).
Export this report as PDF (all source links + data timestamp) · Premium
Request diligence pack (Premium) PartnerFacts asks the sponsor for the standard information pack and delivers it to you labelled "provided by the sponsor".
Corrections log
No corrections have been requested for this page.
Filing-to-filing changes are in Amendment history above.
Email me the full report
The complete public-record profile for Immunome Inc., plus the weekly new-filings list.
What do you want to do?
Only "Connect me" shares your details — with this sponsor, at a flat price we charge them, never tied to whether you invest. "Just researching" shares nothing.
Request a correction
Free. Tell us what's wrong and, if you can, where the correct public record is. Every request is logged with its status (received → under review → fixed / confirmed with source).
Sponsor response
Sponsors may add a sourced explanation next to any fact on this page. Reviewed before publishing; never edits the public record.
Claim this profile (sponsors)
Free. Get the "Claimed by sponsor" chip and a confirmed contact for corrections. Claiming never changes the public-record section.